Literature DB >> 21715577

Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice.

Diana Kouiavskaia1, Marc S Collett, Eugenia M Dragunsky, Andrey Sarafanov, Konstantin M Chumakov.   

Abstract

Immunization of mice with inactivated polio vaccine (IPV) with concurrent dosing of poliovirus antiviral V-073 showed no detrimental impact on the elicitation of serum-neutralizing antibodies. A strategy involving coadministration of antiviral V-073 and IPV can be considered for the management of poliovirus incidents.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21715577      PMCID： PMC3147355          DOI： 10.1128/CVI.05147-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  5 in total

1.  Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Authors:  J Martín; G Dunn; R Hull; V Patel; P D Minor
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  In vitro antiviral activity of V-073 against polioviruses.

Authors:  M Steven Oberste; Deborah Moore; Barbara Anderson; Mark A Pallansch; Daniel C Pevear; Marc S Collett
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

Review 3.  A case for developing antiviral drugs against polio.

Authors:  Marc S Collett; Johan Neyts; John F Modlin
Journal:  Antiviral Res       Date:  2008-05-13       Impact factor: 5.970

4.  Vaccine policy changes and epidemiology of poliomyelitis in the United States.

Authors:  Lorraine Niño Alexander; Jane F Seward; Tammy A Santibanez; Mark A Pallansch; Olen M Kew; D Rebecca Prevots; Peter M Strebel; Joanne Cono; Melinda Wharton; Walter A Orenstein; Roland W Sutter
Journal:  JAMA       Date:  2004-10-13       Impact factor: 56.272

Review 5.  Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.

Authors:  Philip Minor
Journal:  Vaccine       Date:  2009-03-03       Impact factor: 3.641
  5 in total
  4 in total

1.  Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic.

Authors:  Xiaobo Wen; Dianjun Cao; Ronald W Jones; Yasutaka Hoshino; Lijuan Yuan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.

Authors:  Xiaobo Wen; Dianjun Cao; Ronald W Jones; Jianping Li; Shousun Szu; Yasutaka Hoshino
Journal:  Vaccine       Date:  2012-08-09       Impact factor: 3.641

3.  Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.

Authors:  Minetaro Arita; Hirotatsu Kojima; Tetsuo Nagano; Takayoshi Okabe; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

4.  Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.

Authors:  Woo-Jin Shin; Daiki Hara; Francisca Gbormittah; Hana Chang; Byeong S Chang; Jae U Jung
Journal:  MBio       Date:  2018-11-27       Impact factor: 7.867
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.